ArticleFrontiers in oncology2025

Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting.

Sanjib Saha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.